Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod

Fig. 2

A Type I IFN activity in plasma in each individual patient was analyzed at baseline, weeks 4 and 8, and at follow-up week 12, by using a functional receptor assay. B The gene expression of five type I IFN responsive genes, IFI44, IFI44L, IFI6, IFI27, and RSAD2, in the skin was analyzed by real-time PCR. The forest plot shows mean fold changes (log2) of each gene after 8 weeks of treatment. The dashes indicate mean fold changes (log2) after 8 weeks of treatment with paquinimod, and the horizontal bars show 95% CIs

Back to article page